Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 16.75 as of 2026-10-06T09:00:46.499Z.
Consensus retrieved: 2026-10-06T01:33:03.723Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T09:00:46.499Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d95dcb8d5ed02b04acc15863ae7b7cbde7eb014f9d1772cef4014a4bcb8c1a9c
Forward PE Ratio (16.75) = Dated Quote Price ($58.85) / Consensus Forward EPS ($3.51)
FORWARD PE RATIO
16.75
SECTOR MEDIAN · HEALTHCARE
19.33
median of 96 covered companies
CURRENT VS SECTOR MEDIAN
-13.32%
vs the sector median at left
Exelixis, Inc.
Market Cap
$14.79B
Forward PE Ratio
16.75
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Exelixis, Inc. (EXEL) | $14.79B | 16.75 |
| Tempus AI, Inc. (TEM)vs › | $14.64B | N/A |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | 27.39 |
| Solventum Corporation (SOLV)vs › | $15.24B | 12.29 |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 15.90 |
| Baxter International Inc. (BAX)vs › | $12.52B | 11.79 |
| Penumbra, Inc. (PEN)vs › | $12.49B | 67.36 |
| Medpace Holdings, Inc. (MEDP)vs › | $17.32B | 35.26 |
| Revvity, Inc. (RVTY)vs › | $17.56B | 29.39 |
Trailing P/E
18.4
reported TTM EPS
Forward P/E
16.8
consensus EPS · fiscal year ending 2027-01-02
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.51 implies +10.0% EPS growth vs the reported trailing $3.19.
At the dated quote price of $58.85, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-01-02 | $3.51 | $3.36 – $3.58 | 9 | 16.8x |
| 2028-01-02 | $4.13 | $3.63 – $4.87 | 9 | 14.2x |
| 2029-01-02 | $5.12 | $4.00 – $6.53 | 8 | 11.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
